Deciphera Pharmaceuticals to Present Data on its Highly-Selective Small Molecule CSF1R Immunokinase Inhibitor, DCC-3014, at American Association for Cancer Research Annual Meeting 2016

On March 17, Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments targeting the tumor cell and the tumor microenvironment, reported that an abstract highlighting the company’s highly-selective small molecule CSF1R inhibitor, DCC-3014, has been selected for presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2016, taking place April 16-20, 2016 in New Orleans (Press release, Deciphera Pharmaceuticals, MAR 17, 2016, View Source [SID:1234509598]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

DCC-3014 was designed as a highly-specific macrophage immunomodulatory agent based on the company’s Switch Control Inhibitor platform. In preclinical cancer models, DCC-3014 was shown to significantly enhance anti-tumor activity when used in combination with an anti-PD-1 checkpoint inhibitor. Deciphera expects to initiate a Phase 1 clinical trial of DCC-3014 in the second half of 2016.

"We are pleased to present data at the AACR (Free AACR Whitepaper) Annual Meeting 2016 demonstrating DCC-3014’s robust inhibition of the CSF1R kinase, both as a single agent and in combination with an anti-PD1 inhibitor, across a number of cancer models," said Michael D. Taylor, Ph.D., Deciphera’s President and Chief Executive Officer. "We look forward to initiating the first-in-human Phase 1 trial with DCC-3014 later this year."

Details of the Poster Presentations on DCC-3014:
Poster Title: The highly specific CSF1R inhibitor DCC-3014 exhibits immunomodulatory and anti-invasive activities in cancer models
Author: Smith, Bryan D.
Abstract #: 4889
Session: Immune Modulating Agents 2
Date & Time: Wednesday, April 20, 2016, 8:00 AM – 12:00 PM
Location: Halls G-J, Poster Section 2. Poster Board #30